1. Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, Buck A et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005;128:907-21.
  2. Bittner D, Grön G, Schirrmeister H, Reske SN, Riepe MW. (18F)FDG-PET in patients with Alzheimer´s disease: marker of disease spread. Dement Geriatr Cogn Disord 2005;19:24-30.
  3. Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP et al. Radiation Exposure of Patients Undergoing Whole-Body Dual-Modality 18F-FDG PET/CT Examinations. J Nucl Med 2005;46:608 - 13.
  4. Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwil C et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005;32:525-33.
  5. Glatting G, Landmann M, Kull T, Wunderlich A, Blumstein NM, Buck AK et al. Internal radionuclide therapy: The UlmDos software for treatment planning. Med Phys 2005;32:2399-405.
  6. Glatting G, Landmann M, Kull T, Wunderlich A, Blumstein N, Koop B et al. UlmDos - a software tool for voxelbased dosimetry before radionuclide therapy. Biomed. Tech. 2005;50:94-5.
  7. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652-61.
  8. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant 2005;36:1021-6.
  9. Muhlmeier G, Reske SN, Blumstein NM, Volker HU, Maier H. The importance of PET in searching the primary tumor site in CUP patients -- a case report. Laryngorhinootologie 2005;84:516-9.
  10. Münch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Krause BJ et al. Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol 2005;58:777-80.
  11. Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I et al. 188Re- or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol 2005;130:604-13.
  12. Rinnab L, Kufer R, Hautmann RE, Volkmer BG, Straub M, Blumstein NM et al. [Innovative concepts in early cancer detection and staging of localized prostate cancer]. Urologe A 2005;44:1262, 4-6, 8-70, 72-5.
  13. Shapiro KA, Mottaghy FM, Schiller NO, Poeppel TD, Fluss MO, Muller HW et al. Dissociating neural correlates for nouns and verbs. Neuroimage 2005;24:1058-67.